ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2372

Treatment Outcome and Persistence of IL-23 Inhibitors in Real World Cohort of PsA Patients- A Retrospective Study
Abstract Number: 2060

Treatment Patterns And Drug Use In Idiopathic Inflammatory Myopathies. Description Of The First Year After Diagnosis In A Swedish Myositis Cohort.
Abstract Number: 1372

Treatment Patterns and Outcomes After Janus Kinase Inhibitor Discontinuation in Rheumatoid Arthritis: A Real-World Cohort Study
Abstract Number: 1552

Treatment With Anifrolumab Prevents Long-Term Cardiovascular Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study
Abstract Number: 1666

Treatment with Rilzabrutinib was associated with Rapid and Sustained Reduction in Disease Activity in Patients with IgG4-RD Previously Treated or Naïve to B cell Depletion
Abstract Number: 2236

Treatment-induced autoantibodies in Rheumatoid Arthritis patients receiving anti-TNF inhibitors or JAK inhibitors
Abstract Number: 1758

Treg need a MAIT: Investigating the contribution of MAIT cells to impaired UV-induced Treg expansion in lupus photosensitive reactions
Abstract Number: 1768

TREM-1 and TREM-2 Define Inflammatory and Protective Axes in ANCA-Associated Glomerulonephritis
Abstract Number: 1795

Trends and Disparities in Osteoarthritis-Related Mortality in the United States: A 21-Year Analysis (1999-2020)
Abstract Number: 0703

Trends and Disparities in Systemic Sclerosis-related Mortality Rates in the United States from 1999 to 2023
Abstract Number: 1031

Trends and Gender Disparities in Rheumatoid Arthritis Burden in the United States: A Population-Based Time-Trend Analysis Using the Global Burden of Disease Database, 1990–2021
Abstract Number: 1053

Trends in Cost and Utilization of Biologic Medications for Rheumatologic Conditions: A Medicare Claims Study (2013–2022)
Abstract Number: 1407

Trends in Diagnostic Timing and Clinical Features of Axial Spondyloarthritis by Sex and Clinical Subtype: A Multicenter Cohort Over Seven Decades
Abstract Number: 0163

Trends in hospitalization and outcomes among patients admitted with Adult-onset Still’s disease in the United States: INSIGHTS FROM THE NATIONAL INPATIENT SAMPLE (2016-2022)
Abstract Number: 1078

Trends in Hospitalization rate with Lupus in the State of Florida: A retrospective data review from Florida Health Charts from 1992-2023

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].